Ryan Marotta, Assistant Editor

As the pharmacy landscape shifts and evolves, pharmacists across the country continue to work toward a common and crucial goal: gaining legislative recognition as health care providers.

Briviact is an adjunctive treatment for partial-onset seizures in patients aged 16 years and older with epilepsy.

The FDA has approved UCB's brivaracetam (Briviact) as an adjunctive treatment for partial-onset seizures in patients aged 16 years and older with epilepsy.

Most pharmacy technicians are all too familiar with the seemingly endless crowd of patients who come to the pharmacy for cold and cough treatments during the winter.

As a 2018 PharmD candidate at the Auburn University Harrison School of Pharmacy, Anthony Todd has lived out his belief that all patients should have equal access to health care.

Learn about the new drugs and expanded indications approved by the FDA in January 2016.

Walmart is increasing the wages of more than 1.2 million workers in a move that could potentially impact the numerous pharmacy technicians employed by the retail giant.

Like many pharmacy students, Shiny Parsai has long had a passion for helping others by providing health care.

Because diabetes is among the most common conditions for which pharmacies will dispense medications, a number of pharmacy technicians seek to better understand the disease.

Need some relief from angry patients and endless queues? These memes are light-hearted reminders of the struggles that all pharmacy techs experience.

Learn about the new drugs and products approved by the FDA in December 2015.

As part of an effort to better regulate the growing supplement industry, the FDA today announced today the creation of its Office of Dietary Supplement Programs.

For Rebecca Mousseau, a pharmacy student at the University of Illinois at Chicago College of Pharmacy, pharmacists are not only health care providers; they are also educators and leaders.

REMS deemed unnecessary to ensure drug benefits outweigh risks.

With flu season well under way, many pharmacy technicians have found themselves directing a myriad of flu-related questions to pharmacists.

The FDA is eliminating the Risk Evaluation and Mitigation Strategy for type 2 diabetes medications containing rosiglitazone.

The FDA has approved Otonomy's ciprofloxacin otic suspension for the treatment of bilateral otitis media with effusion in pediatric patients who are undergoing tympanostomy tube placement.

The FDA has approved Pfizer's chewable formulation of methylphenidate HCl (QuilliChew ER) for the treatment of ADHD in patients 6 years and older.

Learn about the new drugs and expanded indications approved by the FDA in November 2015.

The FDA has approved Lightlake Therapeutics and Adapt Pharma's naloxone nasal spray to stop or reverse the effects of an opioid overdose.

Salin Nhean, a pharmacy student at the University of Maryland School of Pharmacy, strives to provide quality care to patients across the globe.

Learn about the new drugs and expanded indications approved by the FDA in October 2015.

The FDA has approved GlaxoSmithKline's mepolizumab (Nucala) as an add-on maintenance treatment for severe asthma.

Drugs are delivered via the low-resistance Neohaler inhaler.

The FDA has approved 2 Novartis inhalation powders for the treatment of COPD.

The FDA has approved Endo Pharmaceuticals and BioDelivery Sciences' buprenorphine buccal film (Belbuca) for the management of chronic pain.

The FDA has approved Iroko Pharmaceuticals' 5 and 10 mg meloxicam capsules (Vivlodex) for the once-daily management of osteoarthritis pain.

The FDA has approved Relypsa's patiromer (Veltassa) for the treatment of hyperkalemia, a serious condition in which there is an elevated level of potassium in a patient's blood.

Kelsey Japs, a pharmacy student at the Drake University College of Pharmacy and Health Sciences, is driven by a belief that pharmacists have a duty to help not only the patients in their immediate communities, but also those in need of health care all across the globe.

The FDA today approved Tris Pharma's extended-release amphetamine oral suspension (Dyanavel XR) for the treatment of ADHD in children aged 6 years and older.